Compare ClearPoint Neuro Inc (CLPT) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs PepsiCo, Inc. — how do they compare? ClearPoint Neuro Inc trades at $15.7 (market cap $478.63M), while PepsiCo, Inc. trades at $135.84 (market cap $184.87B). The key difference: PepsiCo, Inc. is far larger — about 386.2× ClearPoint Neuro Inc's market cap, and PepsiCo, Inc. pays a 4.37% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | PEP | |
|---|---|---|
Market Cap | $478.63M | $184.87B |
Sector | Health | Consumer Staples |
52-Week High | $29.60 | $170.44 |
52-Week Low | $8.66 | $133.81 |
Enterprise Value | $506.63M | $227.37B |
Dividend Yield | — | 4.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
PepsiCo (PEP) trades at $138.49, up 0.81% with bearish technical signals but strong fundamentals. The stock shows consistent earnings beats with Q2 2026 EPS of $2.20 exceeding expectations. Revenue growth remains steady at $93.93B in 2025, while profit margins improved to 10.78% net income margin. Recent news highlights price adjustments in snack portfolio and institutional accumulation despite technical headwinds.
PepsiCo presents a mixed outlook with strong fundamentals offset by technical weakness. The company's 33% upside to consensus price target of $159.27 offers potential, but investors face risks from consumer pricing sensitivity and competitive pressures. The stock's high ROE (51.59%) and dividend yield near 4% provide defensive characteristics amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
